Advanced diagnostic methods play an essential role in the increasing acceptance of IEM. In the past, these disorders were often misdiagnosed or overlooked due to limited information and diagnostic tools. However, advances in medical technology and genetic testing have changed our ability to accurately diagnose IEM. Advanced technologies such as next-generation sequencing and biochemical analysis allow healthcare professionals to identify specific genetic mutations or abnormalities in metabolic pathways associated with these disorders. This improved diagnostic accuracy has contributed to the increased incidence of IEM. For instance, advances in next-generation sequencing technology have made it possible to identify rare IEM variants that were previously difficult to locate. This enabled a more accurate and comprehensive diagnosis of these disorders.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-medical-foods-for-inborn-errors-of-metabolism-market
Data Bridge Market Research analyses that the Global Medical Foods for Inborn Errors of Metabolism Market is expected to reach USD 7,998.77 million by 2031 from USD 2,477.81 million in 2022, at a CAGR of 14.1% in the forecast period 2023 to 2031.
Key Findings of the Study
Increasing Spending on Medical Food Products
The increasing spending on medical food products is based on several factors that reflect the growing awareness of their importance in managing the health situation. Firstly, the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and gastrointestinal diseases has led to an increased demand for medical foods that are specially expressed to meet the nutritional needs of people with these diseases. As the number of people with these chronic conditions increases, so does spending on drugs designed to relieve their symptoms and recover overall health.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2031
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Products (Amino Acid, Low Protein Food, Glytactin with GMP Amino Acid-Modified Infant Formula with Iron, Low-Calcium/Vitamin D-Free Infant Formula with Iron, and Others), Diseases (Phenylketonuria (PKU), Ryrosinemia Types I And II, Maple Syrup Urine Disease (MSUD), Homocystinuria, Glutaric Acidemia Type I, Urea Cycle Disorders, Methylmalonic Acidemia, Isovaleric Acidemia, Organic Acidurias, Renal Disease, Propionic Academia, Disorders Of Leucine Metabolism, and Others), Age Group (Infants, Weaning, Adolescent, and Adults), Forms (Powder, Liquid, Tablets , Gels, and Others), Packaging (Can, Jar, Packets, Bottle, and Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, Drugs Store, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Russia, Spain, Belgium, Switzerland, Netherlands, Turkey, rest Of Europe, China, Japan, India, South Korea, Australia, Singapore, Malaysia, Indonesia, Thailand, New Zealand, rest Of Asia-Pacific, Brazil, Argentina, rest Of South America, U.A.E., Saudi Arabia, South Africa, Egypt, and rest of Middle East And Africa
|
|
Market Players Covered
|
Nutricia (Netherlands), Abbott (U.S.), Baxter (U.S.), Nestlé Health Science (U.S.), Meiji Holdings Co., Ltd. (Japan), Hexagon Nutrition Ltd (India), Kate Farms (U.S.), Primus Pharmaceuticals, inc. (U.S.), Promin (U.K.), Ajinomoto Cambrooke, Inc. (U.S.), Galen Limited (U.K.), Piam Farmaceutici S.P.A. (Italy), B. Braun SE (Germany), Pristine Organics Pvt Ltd. (India), Mead Johnson & Company, LLC. (U.S.), Orpharma Pty Ltd. (Australia), EBM Medical (U.S.), Biovencer Healthcare Pvt Ltd ( India), and Solace Nutrition (U.S.), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
The global medical foods for inborn errors of metabolism market is segmented into six segments based on products, age group, diseases, forms, packaging, and distribution channel.
- On the basis of products, the market is segmented into amino acid, glytactin with GMP amino acid-modified infant formula with iron, low-calcium/vitamin D-free infant formula with iron, low protein food, and others
In 2023, the amino acid segment is expected to dominate the global medical foods for Medical Foods for Inborn Errors of Metabolism Market
In 2023, the amino acid segment is expected to dominate the global medical foods for inborn errors of metabolism market with a market share of 41.98%. Due to it has the ability to improve the metabolic activity of patients suffering from IEMs. Major companies are also generating their revenue by providing products including amino acid-based products as medical food for the treatment of IEMs-related diseases. Amino acids are the main source of protein in the body hence, they are highly helpful and recommended by doctors for infants who are suffering from IEMs diseases.
- On the basis of diseases, the global medical foods for inborn errors of metabolism market is segmented into Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), homocystinuria, methylmalonic acidemia, organic acidurias, propionic acidemia, isovaleric acidemia, disorders of leucine metabolism, glutaric acidemia type I, renal disease, tyrosinemia types I and II, urea cycle disorders, and others
In 2023, the Phenylketonuria (PKU) segment is expected to dominate the Medical Foods for Inborn Errors of Metabolism Market
In 2023, the Phenylketonuria (PKU) segment is expected to dominate the global medical foods for inborn errors of metabolism market with a market share of 19.04%. Due to its incidence is high in all IEM diseases. Also, it has been observed that companies are more inclined in manufacturing medical foods for PKU disease.
- On the basis of age group, the global medical foods for inborn errors of metabolism market is segmented into infants, weaning, adolescent, and adults. In 2023, the infants segment is expected to dominate the market with a market share of 48.31%
- On the basis of form, the global medical foods for inborn errors of metabolism market is segmented into powder, liquid, tablets, gels, and others. In 2023, the powder segment is expected to dominate the market with a market share of 51.26%
- On the basis of packaging, the global medical foods for inborn errors of metabolism market is segmented into can, jar, packets, bottle, and others. In 2023, the can segment is expected to dominate the market with a market share of 41.87%
- On the basis of distribution channel, the global medical foods for inborn errors of metabolism market is segmented into retail pharmacy, hospital pharmacy, online pharmacy, drug stores, and others. In 2023, the hospital pharmacy segment is expected to dominate the market with a market share of 52.77%
Major Players
Data Bridge Market Research analyzes Nutricia (Netherlands), Abbott (U.S.), Baxter (U.S.), Nestlé Health Science (U.S.), Meiji Holdings Co., Ltd. (Japan) as major market players in this market.
Recent Developments
- In October 2023, Nestlé Health Science and Amwell announced a collaboration to help health organizations improve patients’ overall health through innovative digital solutions focused on nutrition. Together the companies are developing a portfolio of novel solutions to help improve clinical and financial outcomes. This will enhance the brand image for both the companies
- In October 2023, Galen Limited announced the release of their latest innovative product, PKU Easy Microtabs Plus from their Medical Nutrition range. provides a phenylalanine-free protein substitute, enriched with vitamins, minerals, and the essential and non-essential amino acids. These are specifically designed for individuals with Phenylketonuria (PKU). It will provide its customers a new solution and boost the company’s revenue
- In October 2022, Galen Limited introduced the first solid-dose protein substitution option for Tyrosinemia, called TYR EASY Tablets onto the U.K. market. Tyrosinemia (TYR) patients over the age of 8 can now select from a wider variety of protein substitutes that best suit their daily needs
- In September 2022, Kate Farms announced the availability of Adult Standard 1.4, a high-calorie medicinal formula now offered in chocolate. For patients who need to meet their nutrient needs in fewer servings, such as those undergoing cancer treatment or those with chronic diseases such as ALS, gastroparesis, and Crohn's disease, Kate Farms' Standard 1.4 is a calorie-dense formula option
- In February 2022, Kate Farms introduced the newest shake, Glucose Support 1.2, which was revealed. This groundbreaking, organic, plant-based nutrition smoothie is intended to help control blood sugar as a component of a well-balanced diet. Glucose Support 1.2, the newest product in Kate Farms' line of nutritional products, was carefully developed to provide diabetic patients with substantial plant-based nourishment
Regional Analysis
Geographically, the countries in the global medical foods for inborn errors of metabolism market report are, U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Poland, Finland, Denmark, Sweden, Norway, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, New Zealand, Vietnam, Philippines, Taiwan, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, Bahrain, U.A.E., Kuwait, Qatar, Egypt, Oman, and rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is expected to dominate the Gobal Medical Foods for Inborn Errors of Metabolism Market
North America is expected to dominate the market because its cutting-edge healthcare infrastructure, intensive research endeavors, stringent regulatory oversight, heightened public awareness about these conditions, widespread access to comprehensive insurance coverage, and proactive governmental policies. These factors collectively reinforce North America's position as a leader in providing innovative solutions for managing these rare genetic disorders and hence, the revenue is highly generated in this region.
Asia-Pacific is expected to dominate tand be the fastest growing region in thehe dominant region in the Global Medical Foods for Inborn Errors of Metabolism Market
Asia-Pacific is expected to be fastest growing region in the market due to its competitive advantage in production efficiency and cost-effectiveness.
For more detailed information about the Global Medical Foods for Inborn Errors of Metabolism Market report, click here – https://www.databridgemarketresearch.com/reports/global-medical-foods-for-inborn-errors-of-metabolism-market
